Nutriband (NASDAQ:NTRB) Announces Earnings Results

by · The Cerbat Gem

Nutriband (NASDAQ:NTRB – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($2.13) by $1.81, Zacks reports. Nutriband had a negative net margin of 398.29% and a negative return on equity of 85.40%. The company had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.68 million.

Nutriband Stock Up 1.0%

Shares of NASDAQ NTRB traded up $0.05 during mid-day trading on Friday, hitting $5.02. The company had a trading volume of 5,036 shares, compared to its average volume of 105,640. The company has a current ratio of 4.78, a quick ratio of 4.70 and a debt-to-equity ratio of 0.01. The firm has a 50-day simple moving average of $6.15 and a two-hundred day simple moving average of $6.92. The company has a market capitalization of $60.39 million, a PE ratio of -1.75 and a beta of 1.89. Nutriband has a one year low of $3.72 and a one year high of $11.78.

Analyst Ratings Changes

Several analysts recently commented on NTRB shares. Zacks Research raised Nutriband from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Wall Street Zen cut Nutriband from a “hold” rating to a “sell” rating in a report on Friday, September 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nutriband in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $13.00.

Get Our Latest Report on Nutriband

Institutional Inflows and Outflows

An institutional investor recently raised its position in Nutriband stock. Vanguard Group Inc. grew its stake in shares of Nutriband Inc. (NASDAQ:NTRB – Free Report) by 1.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 202,738 shares of the company’s stock after purchasing an additional 3,111 shares during the quarter. Vanguard Group Inc. owned approximately 1.68% of Nutriband worth $1,429,000 at the end of the most recent quarter. 19.70% of the stock is owned by institutional investors.

About Nutriband

(Get Free Report)

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.

Featured Stories